M

Minneapolis Heart Institute Foundation | Minneapolis, MN

Research site
(Unclaimed)
Location
920 East 28th Street Suite 620, Minneapolis, Minnesota, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

20 of 103
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM)

The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic...

Enrolling
Cardiomyopathy, Hypertrophic
Drug: Mavacamten
Other: Placebo

Prospective, multicenter, randomized, sham-controlled, double blinded, adaptive study designed to evaluate the safety and efficacy of a percutaneousl...

Invitation-only
Heart Failure
Device: Alleviant ALV1 System
Other: Sham-Control

Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Rest...

Enrolling
Dilated Cardiomyopathy
Heart Failure With Reduced Ejection Fraction (HFrEF)
Device: AccuCinch Ventricular Restoration System
Drug: Guideline-Directed Medical Therapy

Combination therapy in pulmonary arterial hypertension (PAH) has been the subject of active investigation for more than a decade, with the benefit of...

Active, not recruiting
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Drug: Tadalafil 40 mg
Drug: Placebo FDC

The purpose of this study is to demonstrate substantial equivalence in terms of safety to support an indication change related to the usage of Preven...

Enrolling
Orthopedic Surgery
Vascular Surgery
Device: Prevena Plus Incision Management System with Prevena Dressings

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults wi...

Active, not recruiting
Coronary Heart Disease (CHD)
Drug: Evolocumab
Drug: Placebo

The aim of the TARGET-IV NA trial is to demonstrate the clinical non-inferiority of the Firehawk® rapamycin eluting stent system in comparison to cur...

Active, not recruiting
Coronary Artery Disease
Device: 2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)
Device: Microport Firehawk stent

Multi-center, double-blind, placebo-controlled, parallel group design. Patients with myocarditis will be screened and, if eligible, randomized within...

Enrolling
Acute Myocarditis
Drug: CardiolRx
Status recently updated

Patients with recurrent pericarditis who are refractory or intolerant to current therapeutic management options or who require long-term administrati...

Enrolling
Active, not recruiting
Recurrent Pericarditis
Drug: CardiolRx

The LEADR study is designed to assess the safety and efficacy of the Next Generation ICD lead.The LEADR LBBAP study is being conducted under the exis...

Active, not recruiting
Tachyarrhythmia
Device: Defibrillation (LBBAP Implant)
Device: Defibrillation (RV Implant)

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (C...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Olpasiran

The purpose of this trial is to determine the safety and effectiveness of the Edwards SAPIEN 3 transcatheter heart valve and delivery systems which a...

Active, not recruiting
Symptomatic Severe Aortic Stenosis
Device: TAVR

To evaluate the safety and effectiveness of the Model 400 aortic valve bioprosthesis.

Active, not recruiting
Aortic Stenosis
Device: Model 400 aortic valve bioprosthesis

This is a prospective, open- label, single arm, multicenter clinical trial to evaluate the safety and effectiveness of the Cordella PA Sensor System...

Active, not recruiting
Heart Failure NYHA Class III
Device: Cordella™ Pulmonary Artery Sensor System

This is a prospective, multi-center, open label, randomized control clinical trial evaluating the safety and efficacy of the Cordella™ Pulmonary Arte...

Enrolling
Heart Failure NYHA Class II
Heart Failure NYHA Class III
Device: Cordella™ Pulmonary Artery Sensor System

Multicenter, Prospective, Randomized Controlled, Blinded Trial, with a Non-implant Control group; 1:1 randomization.

Active, not recruiting
Heart Failure
Device: IASD System II implant
Other: intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)

The purpose of this study is to test the hypothesis that renal denervation decreases blood pressure and is safe when studied in the presence of up to...

Active, not recruiting
Hypertension
Cardiovascular Diseases
Device: Symplicity Spyral™ multi-electrode renal denervation system
Procedure: Sham Procedure
Locations recently updated

Safety and performance evaluation of the preCARDIA System for patients with ADHF.

Enrolling
Acute Heart Failure
Acute Decompensated Heart Failure
Device: preCARDIA system

The objective of the RADIANCE II Pivotal study is to demonstrate the effectiveness and safety of the Paradise System in subjects with Stage 2 hyperte...

Active, not recruiting
Hypertension
Cardiovascular Diseases
Procedure: Renal Angiogram
Device: Paradise Renal Denervation System

The TricValve® Transcatheter Bicaval Valve System is a bicaval transcatheter tricuspid valve implantation system, which includes the TricValve® Trans...

Not yet enrolling
Tricuspid Valve Disease
Tricuspid Regurgitation
Device: TricValve® Transcatheter Bicaval Valve System
Procedure: Medical Therapy Arm

Trial conditions

Heart Failure (18 trials)
Coronary Artery Disease (14 trials)
Myocardial Infarction (10 trials)
Aortic Valve Stenosis (8 trials)
Cardiomyopathies (8 trials)
Infarction (8 trials)
Cardiovascular Diseases (7 trials)
Ischemia (7 trials)
Myocardial Ischemia (7 trials)
Peripheral Arterial Dise... (6 trials)

And 54 more

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems